Top View
- 2018 Medicines in Development for Cancer
- Repositioning of Tyrosine Kinase Inhibitors As Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
- Masivet-Epar-Scientific-Discussion En.Pdf
- OCTOBER 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Download Report
- Tyrosine 370 Phosphorylation of ATM Positively Regulates DNA Damage Response
- AB SCIENCE Press Release 21 11 13 EN FINAL
- 2021 ASCO Direct Highlights at South Carolina Oncology Society Annual Conference: Gastroesophageal, Pancreatic, Hepatobiliary
- Methotrexate Sensitizes Drug-Resistant Metastatic Melanoma Cells to BRAF V600E Inhibitors Dabrafenib and Encorafenib
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- Scientific Report 2019
- Effects of Tyrosine Kinase Inhibitor-Masitinib Mesylate on Canine Mammary Tumour Cell Lines
- (BRAF V600 Mutation Positive, Unresectable Metastatic
- Masitinib – a Targeted Therapy with Applications in Veterinary Oncology and Inflammatory Diseases
- Overcoming Resistance to BRAF Inhibitors
- Gastrointestinal Stromal Tumours After Treatment with Imatinib
- ATC/DDD Classification (Final)
- Masitinib for Gastrointestinal Stromal Tumours – Second Line June 2012
- Masitinib, a C-Kit/PDGF Receptor Tyrosine Kinase Inhibitor, Improves Disease Control in Severe Corticosteroid-Dependent Asthmatics
- Oncofocus® Precision Oncology
- Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
- Study Protocol and Statistical Analysis Plan
- Masipro, Through the Centralised Procedure Falling Within the Article 3(1) and Point 4 of Annex of Regulation (EC) No 726/2004
- Oncofocus Patient Test Report
- Changelog (In Alphabetical Order of the Value Set) Value Set Code Description Change
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
- Breast Cancer Cancer Drug Pipeline Information for Patient Advocacy
- Tyrosine Kinase Inhibitors in Veterinary Medicine
- Comparative Analysis of the Kinase Selectivity Profile of Masitinib and Its Competitors in Clinical Trials Summary
- Resistance to Molecularly Targeted Therapies in Melanoma
- A View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Masivet, Masitinib Mesylate
- Oncology Drugs in the Pipeline
- Anticancer Drugs Repurposed for Alzheimer's Disease: a Systematic
- Masitinib Antagonizes ATP-Binding Cassette Subfamily G Member 2-Mediated Multidrug Resistance
- A Randomized, Placebo-Controlled, Phase 3 Study of Masitinib for Treatment Of
- Drug Repurposing Screen Identifies Masitinib As a 3Clpro Inhibitor That Blocks Replication of SARS-Cov-2 in Vitro
- Antiproliferative Effects of Masitinib and Imatinib Against Canine Oral Fibrosarcoma in Vitro
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- A Potent and Selective Tyrosine Kinase Inhibitor Targeting
- Evolving Therapeutic Strategies Maintain Clinical Momentum in Melanoma Jane De Lartigue, Phd
- Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10–Mediated Paclitaxel Resistance: a Preclinical Study
- Applications for New Human Medicines Under Evaluation by the Committee for Medicinal Products for Human Use November 2012
- Supplementary Materials
- Prescribing Outlook New Medicines 2013
- Extracellular Domain C-Kit Mutation with Duplication of Ser501ala502